GT
MIRM icon

Glenmede Trust’s Mirum Pharmaceuticals MIRM Stock Holding History

Glenmede Trust’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$647K Sell
5,529
-3
-0.1% -$301 ﹤0.01% 897
2026
Q1 		$511K Buy
5,532
+2,217
+67% +$209K ﹤0.01% 952
2025
Q4 		$262K Buy
+3,315
New +$238K ﹤0.01% 1200

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Glenmede Trust's MIRM Position: Q2 2026 in Review

Glenmede Trust reduced its Mirum Pharmaceuticals (MIRM) stake by 0.05% in Q2 2026, selling an estimated $301 and leaving 5,529 shares worth $647K. The position accounts for ﹤0.01% of the portfolio, ranked #897.

Glenmede Trust first reported a position in MIRM in Q4 2025 and has held it in 3 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Glenmede Trust held 5,529 shares of Mirum Pharmaceuticals worth $647K as of Q2 2026.
  • Glenmede Trust sold 3 Mirum Pharmaceuticals shares in Q2 2026, an estimated $301.
  • Mirum Pharmaceuticals made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #897 holding.
  • Glenmede Trust first reported a position in Mirum Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.